You are here


MEK Inhibitor Selumetinib (AZD6244) in Combination With the Dual mTOR Kinase Inhibitor Vistusertib (AZD2014) for Patients With Malignant Peripheral Nerve Sheath Tumors
Type of Sarcoma: 
Unresectable or Metastatic NF1 Associated or Sporadic Malignant Peripheral Nerve Sheath Tumors (MPNST)
Selumetinib in combination with Vistusertib
Accrual Status: 
Not Yet Recruiting
Overall Study Principal Investigator: 
AeRang Kim, MD, PhD
Pediatric Oncologist
Children’s National Medical Center

Brigitte Widemann, MD
Senior Investigator, Pediatric Oncology Branch
National Cancer Institute

For more information about this trial and open sites: